•Product planning and value positioning
•Market Access:
- pricing;
- reimbursement list including "7 Nosologies";
- HTA strategy and Dossier;
- MA environment training;
- comments and criticism from RF Ministry of Health and interpretation of these in the context of russian healthcare system.
•Evidence Generation:
- scientific communications / literature reviews;
- disease burden/need analyses;
- regulatory pathway observations;
- rare diseases;
- pushing into reimbursement list.
•Pharmaco-economic and statistics:
- cost effectiveness argumentation of developing and adaptation;
- budget impact data;
- use of ITC;
- micro and macro economic;
- biostatistics;
- digital economic models and presentations.
•Public Health and Epidemiology:
- late phase and observational studies;
- institutional partnerships;
- evaluation of health policy and epidemiological programs.
